Laboratory documentation is moreover available for Retatrutide
Written by Ali Rza Akn Microbiome Scientist, Author & Founder of Next-Microbiome Ali Rza Akn is a microbiome scientist with nearly 30 years of experience in translational biotechnology, systems biology, and applied microbiome research, spanning discovery, preclinical development, and clinical-stage translation
Retatrutide is an investigational injectable triple agonist targeting GLP-1, GIP, and glucagon receptors, currently in clinical trials for obesity and type 2 diabetes but not yet approved by the MHRA or EMA
Its used to treat type 2 diabetes and has also shown benefits for people looking to improve weight and overall metabolic health
In this case, 5-h-fasted mice were intraperitoneally administered with 0.75 U of insulin (Sigma-Aldrich, MO, USA) per kg body weight, and blood glucose concentrations were determined before (0) and at 15, 30, 60, and 120 min after insulin injection